RyosukeTsugitomi· @Rtsugitom · X·· 1 天前评分70
正文
暂无中文译文，显示英文原文。
A much larger difference than anticipated!
#ESMO26
18 浏览 · 0 赞 · 0 转发 · 1 回复
Two highly anticipated studies will be presented at today's Presidential Symposium #ESMO26 ① KRASCENDO-1: Results from a head-to-head trial comparing two KRAS inhibitors in patients with KRAS G12C-mutated NSCLC在 X 查看被引用的帖子
帖内回复
- RyosukeTsugitomi@Rtsugitom
Is sotorasib becoming the crizotinib eventually superseded by a newer inhibitor, just as alectinib replaced crizotinib in ALK-positive NSCLC..? Thank you sotorasib, for the past. All glory to divarasib, the future!
来源：RyosukeTsugitomi · x.com